Glucose‐lowering action through targeting islet dysfunction in type 2 diabetes: Focus on dipeptidyl peptidase‐4 inhibition

Åhrén, Bo

doi:10.1111/jdi.13564

Cited by 7 publications

(4 citation statements)

References 91 publications

(108 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ценные наблюдения, характеризующие отдельные аспекты действия этой группы препаратов как при СД 2-го типа, так и в других ситуациях, можно обнаружить и в ряде других работ последнего времени. Например, получили дальнейшее подтверждение данные о непосредственном влиянии иДПП-4 на функции альфа-и бета-клеток островков Лангерганса (блокирующий и стимулирующий), причем более выраженном у жителей восточных регионов мира по сравнению с европеоидной группой, что, по мнению авторов, открывает путь для прецизионной медицины в этом направлении [4].…”

Section: идпп-4 -очевидноеunclassified

Inhibitors of dipeptidyl-peptidase-4: obvious and probable (literature review)

Ортенберг

Суплотова

2022

Medicinskij sovet

View full text Add to dashboard Cite

The purpose of the presented literature review was an attempt to sum up current estimates of the effect of the use of dipeptidyl peptidase-4 inhibitors (iDPP-4) in the algorithms of both traditional (diabetes mellitus) and a number of alternative nosologies, in particular, oncological and neurological pathology, as well as a new coronavirus infection (COVID-19). To do this, the most large-scale (as a rule) publications of 2018–2021 devoted to the problems under consideration were analyzed. The search was carried out by keywords in the Pubmed information base (ncbi.nlm.nih.gov). Factors contributing to the widespread use of IDP-4 in clinical practice are both pharmacologically clear mechanism of action and efficacy, as well as the possibility of oral use, a successful pharmacokinetic profile, low toxicity, in particular, a low risk of hypoglycemia. Newly obtained data on the mechanisms of mechanisms are discussed. Renoprotective action, the presence of cardioprotection is debated. The biochemical prerequisites for the possible effectiveness of iDPP-4 as blockers of the development of a hyperimmune reaction that causes, in particular, the severe course of the new coronavirus infection are discussed. At the same time, the results of studies of various designs are categorically compared, indicating both in favor of the use of iDPP-4 in patients with COVID-19, and not noticing its expediency. It is concluded that, given the large-scale biochemical role of DPP-4, it is important both to continue the active use of its inhibitors in diabetes mellitus, and to expand attempts to use them in a number of other nosologies, including COVID-19.

show abstract

Section: идпп-4 -очевидноеunclassified

Inhibitors of dipeptidyl-peptidase-4: obvious and probable (literature review)

Ортенберг

Суплотова

2022

Medicinskij sovet

View full text Add to dashboard Cite

show abstract

“…Dipeptidyl peptidase-4 (DPP-4) inhibition is a glucose-lowering medication, stimulating insulin secretion and inhibiting glucagon secretion in a glucose-dependent manner, with poor risk of hypoglycemia in adults. However, no strong evidence of its use in children has been demonstrated so far [69,70].…”

Section: Treatmentmentioning

confidence: 99%

Insulin resistance in children

Mainieri¹,

Tagi²,

Chiarelli³

2022

Current Opinion in Pediatrics

View full text Add to dashboard Cite

Purpose of reviewInsulin resistance (IR) is a clinical condition due to the decline in the efficiency of insulin promoting glucose uptake and utilization. The aim of this review is to provide an overview of the current knowledge on IR in children, focusing on its physiopathology, the most appropriate methods of measurement of IR, the assessment of risk factors, the effects of IR in children, and finally giving indications on screening and treatment.Recent findings IR has evolved more and more to be a global public health problem associated with several chronic metabolic diseases.

show abstract

“…Epidemiological data have convincingly demonstrated that the most evident risk factors for BP are certain neurological diseases ( 4 – 7 ) and the use of dipeptidyl peptidase 4 (DPP4) inhibitors (gliptins) ( 8 – 14 ). Gliptins are oral anti-diabetic drugs that are widely used to treat type 2 diabetes (T2D) ( 15 ), but the exact mechanism by which the use of gliptins increases the risk for BP is unknown ( 13 ). Furthermore, data about the clinical and immunological similarities and differences of regular BP (rBP) and gliptin-associated BP (BP+g) are scarce and partially conflicting ( 13 ).…”

Section: Introductionmentioning

confidence: 99%

Use of gliptins reduces levels of SDF-1/CXCL12 in bullous pemphigoid and type 2 diabetes, but does not increase autoantibodies against BP180 in diabetic patients

et al. 2022

View full text Add to dashboard Cite

The use of dipeptidyl peptidase 4 (DPP4) inhibitors, (also known as gliptins), is associated with an increased risk of bullous pemphigoid (BP), an autoimmune blistering skin disease. To explore the mechanism behind gliptin-associated BP we investigated circulating autoantibodies against the major BP autoantigen BP180 in serum samples from patients with type 2 diabetes (T2D) with preceding gliptin medication (n = 136) or without (n = 136). Sitagliptin was the most frequently prescribed gliptin (125/136 patients). Using an ELISA assay, we showed that IgG autoantibodies against the immunodominant NC16A domain of BP180 were found in 5.9% of gliptin treated and in 6.6% of non-gliptin treated T2D patients. We found that 28% of gliptin treated patients had IgG autoantibodies recognizing the native full-length BP180 in ELISA, but among non-gliptin treated the seropositivity was even higher, at 32%. Further ELISA analysis of additional serum samples (n = 57) found no major changes in the seropositivity against BP180 during a follow-up period of about nine years. In immunoblotting, full-length BP180 was recognized by 71% of gliptin treated and 89% of non-gliptin treated T2D patients, but only by 46% of the age-and sex-matched controls. The chemokine stromal derived factor-1(SDF-1/CXCL12) is one of the major substrates of DPP4. Immunostainings showed that the expression of SDF-1 was markedly increased in the skin of BP patients, but not affected by prior gliptin treatment. We found that the use of gliptins decreased the serum level of SDF-1α in both BP and T2D patients. Our results indicate that the autoantibodies against the linear full-length BP180 are common in patients with T2D, but seropositivity is unaffected by the use of sitagliptin.

show abstract

Glucose‐lowering action through targeting islet dysfunction in type 2 diabetes: Focus on dipeptidyl peptidase‐4 inhibition

Cited by 7 publications

References 91 publications

Inhibitors of dipeptidyl-peptidase-4: obvious and probable (literature review)

Inhibitors of dipeptidyl-peptidase-4: obvious and probable (literature review)

Insulin resistance in children

Use of gliptins reduces levels of SDF-1/CXCL12 in bullous pemphigoid and type 2 diabetes, but does not increase autoantibodies against BP180 in diabetic patients

Contact Info

Product

Resources

About